Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/zibotentan - AstraZeneca

Next Previous
X
Search
Drug Profile

Dapagliflozin/zibotentan - AstraZeneca

Alternative Names: Zibotentan/dapagliflozin - AstraZeneca

Latest Information Update: 19 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Anti-ischaemics; Antihyperglycaemics; Antineoplastics; Antivirals; Benzhydryl compounds; Cardiovascular therapies; Chlorobenzenes; Glucosides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Oxadiazoles; Pyrans; Pyrazines; Pyridines; Small molecules; Sulfonamides; Urologics
  • Mechanism of Action Endothelin A receptor antagonists; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal failure
  • Phase II Liver cirrhosis

Most Recent Events

  • 05 Jun 2024 Efficacy and adverse event data from a phase IIb trial in Liver cirrhosis presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
  • 21 Feb 2024 AstraZeneca plans a phase II ZEAL UNLOCK trial for Liver cirrhosis in Australia, Belgium, Czech Republic, Germany, Italy, Japan, Poland, Slovakia in February 2024 (PO)(NCT06269484)
  • 15 Feb 2024 Phase-II clinical trials in Liver cirrhosis in Belgium, Czech Republic, Germany, Poland, Italy, Slovakia (PO) (NCT06269484) (EudraCT2023-506893-11-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top